For many patients with gastroesophageal reflux disease (GERD), proton pump inhibitors (PPIs) remain the treatment of choice, according to David Armstrong, MA, MB, BChir, FRCP (UK), FRCPC, FACG, AGAF, and colleagues. “However, despite PPI therapy, many patients with GERD continue to be symptomatic,” they write.
Trending
- Iterative Health Closes $77 Million Series C to Accelerate the Future of Clinical Research (Business Wire)
- Private Equity vs. Independent Medicine: When Wall Street Enters the Exam Room (Working Healthcare – the Podcast Fixing Healthcare)
- Artificial Intelligence Is Not the End of the Physician (JAMA)
- Charted: The most (and least) burned out physician specialties (Advisory Board)
- Growth, practice value and mergers: A strategic guide for physicians (Medical Economics)
- The potential ‘litigation wave’ headed for GI (Becker’s GI & Endoscopy)
- Groundbreaking new study shows real-time AI platform better at diagnosing cancer than biopsy (UMass Chan Medical School)
- Investigational endoscopic therapy maintains weight after GLP-1 discontinuation (GI & Hepatology News)
